Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
7/2022 ceased to operate
SciCann Therapeutics
SciCann Therapeutics Overview
SciCann Therapeutics is a CanadianIsraeli pharmaceutical company that develops and commercializes pharmaceutical products that target and modulate the endocannabinoid system, including new therapeutic agents, drug candidates, novel cannabis genetics, and personalized treatment tools.
SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases, and inflammatory disorders. The company develops a line of proprietary products for the treatment of chosen life-threatening conditions that present a high level of unmet need.
SciCann Therapeutics holds a diversified portfolio of intellectual property and ownerships in ventures operating in cannabinoid science. It maintains a wide network of strategic and synergistic collaborations with research institutes and commercial companies in the space. The company's R&D is performed in Israel with commercialization in Canada.
SciCann Therapeutics Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
Oct 2, 2019
www.globenewswire.com
SciCann Therapeutics receives notice of allowance for its enhanced CBD therapy US patent for NASH
#Investment
Feb 21, 2019
www.globenewswire.com
SciCann Therapeutics launch liver disease research program in Tel Aviv University
#Partners
Nov 29, 2018
www.businesswire.com
FSD Pharma and SciCann Therapeutics to Present at the iCDP Summit in Boston
undefined
Nov 6, 2018
www.globenewswire.com
SciCann Therapeutics Announces Positive ISA Report for "Steady Stomach" CBD Combination Therapy Patent
#Partners
Sep 23, 2018
www.newswire.ca
FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University